Method for treating precancer pathology of uterine cervix

FIELD: medicine, gynecology, oncology.

SUBSTANCE: the present innovation deals with treating pre-cancer pathology of uterine cervix in women with either bacterial or viral infection. One should affect the tissues of uterine cervix with low-intensity infrared radiation of semiconductor laser at wave length being 0.89 nm, frequency of 80 Hz, power of 6 W. Simultaneously, one should perform hypervenous blood photomodification in projection area of left elbow vein and sternum, per 2.5 min for every area. Hypervenous blood photomodification should be carried out with the help of a matrix emitter MLOK-6. Laser impact should be fulfilled due to application of "Mustang-bio" apparatus, emitting head LO-2 and a gynecological headpiece G-1.

EFFECT: higher efficiency of therapy.

2 cl, 1 ex, 1 tbl

 

The invention relates to medicine, specifically to gynecology and Oncology, and can be used in the treatment of precancerous cervical pathology in young women.

There is a method of treatment cryosurgery, which over the last 15-20 years has experienced significant growth as a method of treatment of precancerous pathology. As cooling agents using liquid nitrogen boiling point 196°With, nitrous oxide is the boiling point 89°C. To conduct manipulations applied krisanda various forms, selected in accordance with the size and shape of the pathological area. Freezing produce until the rim of frost on the surface of the cervix width of 2-2,5 cm, handle and part of the cervical canal. When the cryogenic is the destruction of cell structures, denaturation of proteins, destruction hypoproteinemia complexes and biological membranes [Rusakevich PS cervix uteri / Minsk: 2000 - S].

The main disadvantage of this technique is the long-term allocation of exudate from the genital tract and the significant terms of regeneration. Due to violations of biological barriers in the presence of chronic foci of infection especially specific, it leads to inflammatory diseases, and also facilitates the transition of pathological changes in more severe; retsidiviruyushchego in 20% of patients treated by this technique. There is a method of treatment determinirovannii methods:

Diathermocoagulation - the influence of high-frequency current to the tissue of the cervix through the dense applying Pugacheva electrode to the affected areas of the cervix. First treat the surface of the front lips of the vaginal part of the cervix, then back and in a circular motion lower third of the cervical canal.

The diathermoconisation method electrosurgical excision of the diseased cervix with the apex of the cone directed toward the internal fix. Guide rod electrode is introduced into the cervical canal to a depth of from 5 to 15 mm, the voltage picked individually. The electrode rotates clockwise with simultaneous pressure on him depending on the desired height of the cone. Remove 2/3 of the cervical canal [Krasnopolsky V. Pathology of the vagina and cervix / M 1997 - .183-184].

The General lack determenirovana methods is that in the presence of foci of specific latent infection occurs exacerbation of inflammatory diseases of small pelvis, as well as the progression of pathological changes and transformation in more severe; the use of electrocoagulation is possible only if the localization of the nidus in the surface layers of the stratified squamous epithelium; the recurrence reach 7-32%.

From the local treatment of high-energy laser (carbon dioxide laser, YAG garnet with neogynon, holmium, argon, potassium titanium phosphate). As a result of intensive absorption of light radiation tissue instantaneously heated to high temperatures. The evaporation of extracellular and intracellular fluid, coagulation and vaporization of cellular structures with the formation of the zone of coagulation necrosis. Cut tissue through a focused laser radiation. First process the posterior lip of the cervix, then the front area of the external OS and the lower third of the cervical canal. The depth of removal of tissues from 1 to 10 mm depending on the degree of cervical dysplasia. [Kustarev V.N., Linda V.A. cervical Pathology / St. Petersburg, 2002. - S-127].

Disadvantages should be considered: the high cost of the method; the inability visual monitoring of coagulation in the distribution process above the bottom third of the canal of the cervix; laser coagulation amid chronically existing foci of infection reduces its effectiveness, impairs tissue regeneration, can aggravate inflammatory diseases; disease recurrence 7-12%.

The known method intravaginal exposure of endocervicitis with the use of vaginal packing, lubricated the relevant disease and the flora of the drug, and gynecological nozzles LO-2 using the apparatus "Mustang-bio" (Bolin VA Niskin ensigna laser therapy in gynecology. A book published. M., 1997, p.16-17).

Object of the invention is the treatment of precancerous cervical pathology in young women, is caused by specific latent infection.

The problem is solved in that in the method of treatment of precancerous cervical pathology caused by specific latent infection, including the impact on cervical tissue of low-intensity infrared semiconductor laser with a wavelength of 0.89 nm, a frequency of 80 Hz, power 6 W, together with the impact on cervical tissue carry out the venous photomodification blood in the area of projection of the left cubital vein and the sternum, 2.5 minutes in each area.

The problem is solved also by the fact that venous modification of the blood is performed using a matrix emitter MLOC-6.

The problem is solved also by the fact that the laser is carried out with the use of the device “Mustang-bio”, the radiating head LO-2 and gynecological attachment G-1.

The technical result of the invention is to improve the cytological indicators of immune and interferon status.

At the stage of preparation for invasive method affect the cervical tissue of low-intensity infrared semiconductor laser using device "Mustang-bio" with a wavelength of 0.9 nm, a frequency of 80 Hz, the power of 6 watts.

Due to the dispersion of the radiation source, luminous flux affects a larger volume of biological tissues compared with the scatter radiation. The methodology includes a combination of intravaginal exposure to laser radiation with a venous photomodification blood in young women with cervical dysplasia varying degrees with the identified latent flowing bacterial or viral sexually transmitted infection. Intravaginal laser irradiation is carried out with the use of gynecological attachment G-1 with a pre-worn a condom on it. Use radiant head LO-2. The venous photomodification blood, make use of a matrix emitter MLOC-6, which is located in the area of projection of the left cubital vein and the sternum. Power, frequency radiation, wavelength identical with the laser radiation.

The use of low-intensity laser radiation has a vasodilating effect, which helps to improve hemo - and lymphocirculation and metabolic processes in tissues, accelerates regeneration due to restoration of natural self-regulation of blood flow at the site of pathology. Has anti-inflammatory action, provides the best conditions for transport of drugs to the hearth. The absence of relapse obpl is established with representation from the stimulation laser radiation factors of nonspecific defense.

The method is as follows. Treatment of women with this pathology begin on day 5-7 of the menstrual cycle with the use of immunomodulators (Likopid), chelators (politeam), antioxidants (vitamin E), interferon inductors (cycloferon, Viferon) using laser therapy apparatus "Mustang-bio". The treatment course is 10 sessions, the duration of the session 5 minutes. Before the session of the cervix is applied ointment application based on identified infectious agent. At the same time spend the venous photomodification blood matrix emitter MLOC-6, located in the projection of the left cubital vein and the sternum. The exposure time of 2.5 minutes in each area. The treatment course consists of 10 sessions.

The control effect of the treatment is carried out after 14 days. The question of further invasive decide on the inspection results of Cytology, follow-up research the scraping of the cervix polymerase chain reaction to infection identified on initial examination and colposcopy.

Example. We have analyzed the results of treatment of 25 women with morphologically confirmed diagnosis of cervical dysplasia II-III degree. The average age was 26.7±1,03 years. Syndrome dysplasia of the cervix in all patients included chronic recurrent Bel is, when standard medical impact on the identified pathogenic vaginal flora did not give lasting cure. 9 women in the interval 4,01±0,7 years had chronic cervical erosion, chronic endocarditis, endocervicitis. In 7 (28%) patients had subacute chronic adnexitis. In the interval from 2 to 5 years at 28% (n=7) patients after electrocoagulation of the cervix was noted relapse background pathology, while 24% (n=6) women epithelization period of the cervix performed after 2-3 months ago cryosurgery was aggravated by dysplastic changes. In addition, 2 (8%) patients had recurrence of dysplastic changes severe in the cervix through 1 month after geotermoelectrica.

In 100% of cases conducted infectious screening by polymerase chain reaction for the presence of chlamydia, ureaplasmas, cytomegalovirus, herpes simplex virus type 2, papilloma virus high risk types 16, 18, 31, 35 in the biopsy of the cervix. Conducted cytological and morphological study of the material from the cervix, the control of immune and interferon status (table). Noted a direct correlation between the presence of dysplastic changes in the cervix during a specific infectious agent: a mixed infection prevailed in 76% (n=19) women and monoinfection 24% (n=6) patient is.

Table

Changes in the cervix according to the results of cytological studies
Changes in the cervixThe number of patients
 Abs%
11.DysplasiaII degree624
  III degree1144
22.Suspected cancer832
TOTAL25100

Morphologically in the tissues of the cervix along with hyperplastic cells of the basal and parabasal layers in all cases was determined by mononuclear and polymorphonucleocytes infiltration, multinucleated cells, giant cells with vacuolization of the kernel. Immunological marked by pronounced defects In T and b systems of immunity, decreased phagocytic activity of leukocytes, persistent failure γ-stimulated interferon.

The treatment by the proposed method. In 80% of patients evaluated and treated subjected to a sexual partner. The results evaluated 14 days after exposure to cervical tissue low is intense infrared laser radiation semiconductor laser in combination with a venous photomodification blood. The efficiency of this method reliably documented by: cytological control of the stroke of the cervical canal; research scraping of the cervix polymerase chain reaction for specific infections that occurred during the primary survey; morphological study of a fragment of the cervix to exclude specific changes; the results of immune and interferon status in the dynamics.

The results of cytological examination of smears from cervical canal in the dynamics is not marked pathological changes in any case. Morphological study of a fragment of the cervix revealed complete regression of dysplastic changes in 21 (84%) patients. In all cases, the disappearance of the giant and polynuclear cells, mononuclear and polymorphonuclear infiltration or she acquired focal nature while maintaining phenomena dysplasia. In 4 (16%) cases of cervical dysplasia remained I-II degree, which was a result of the expressed disturbances of the immune status and/or inadequate in terms of treatment.

Slickest identified specific sexually transmitted infections, was 96%. Only 1 (4%) patients aged 45 years at the primary control after 14 days remained papillomavirus 16 type but in the process of dynamic observation for 2 months on the background of originalmay immunotherapy virus was eliminated. Bleeding after exclusion of scabs, pus formation is not observed in any case. The duration of complete epithelialization cervical ranged from 25 to 35 days, which is the prevention of endometriosis. After epithelization neck remained elastic, there was no hypertrophy, cicatricial changes. Relapses during dynamic observation is not marked.

1. The method of treatment of precancerous cervical pathology caused by specific latent infection, including the impact on cervical tissue of low-intensity infrared semiconductor laser with a wavelength of 0.89 nm, a frequency of 80 Hz, power b W, characterized in that simultaneously with the impact on cervical tissue carry out the venous photomodification blood in the area of projection of the left cubital vein and the sternum, 2.5 min for each area.

2. The method according to claim 1, characterized in that the venous photomodification blood is performed using a matrix emitter MLOC-6.

3. The method according to claim 1, characterized in that the laser is carried out with the use of the device “Mustang-bio”, the radiating head LO-2 and gynecological attachment G-1.



 

Same patents:

FIELD: medicine, surgery.

SUBSTANCE: one should introduce solution "Rheamberin 1.5%"intravenously with infusomates at the dosage of 5 ml/kg/d during the next 5 d. Then, 1-2 h later, one should infuse intravenously "Dalargin" at 30 mg/kg/d dissolved in 60 ml 0.9% sodium chloride at the rate of 120 ml/h for 5 d. Additionally, 4-5 h after "Dalargin" injection it is necessary to perform daily intravenous He-Ne laser irradiation of blood beginning since the first day at wave length being 0.63 mcm, power 1 mW, exposure 50-60 min, course lasts for 5 d. The method enables to interrupt intestinal paresis in case of vertebral traumas and wounds in earlier terms.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, gastroenterology.

SUBSTANCE: laser therapy should be prescribed at differentiated mode. In case of primarily detected pathology or disease duration for under 10 years or rarely relapsing form and availability of pronounced pain syndrome cutaneous impact should be performed at wave length of 0.89 mcm, impulse power of 5-7 W, impulse frequency of 80-150 Hz, by contact-stable technique for standard fields of impact, impact time being 64-128 sec/field, about 10-12 procedures/course. In case of disease duration being above 10 years in elderly groups, at pronounced astheno-autonomic syndrome and at no or unpronounced pain syndrome one should conduct intravenous laser impact at wave length of 0.63 mcm, radiation power at the edge of a disposable intravenous light guide being 1-1.5 mW, duration of procedure being 20 min, 7 procedures/course. Combined method deals with daily successive intravenous and cutaneous impact according to the above-mentioned technique - in case of disease duration above 10 years, frequently relapsing form, availability of multiple or combined ulcers and availability of two or more parallel diseases. The method enables to decrease terms of hospitalization, decrease frequency of exacerbations and prolong remission period.

EFFECT: higher efficiency of therapy.

1 dwg, 2 ex, 2 tbl

FIELD: medicine, gynecology.

SUBSTANCE: one should perform surgical destruction of endometrioidal heterotopias, antibioticotherapy followed by hormone-modulating therapy. Moreover, it is necessary to irradiate blood through a monofilamentous quartz light guide introduced into patient's elbow vein with the help of He-Ne laser at wave length being 628 nm at 15 min duration during the first 5 procedures and for 30 min during 2 last procedures followed by prescribing GnRH agonists for 7 d at the background of antibioticotherapy, intake of analgetics and vobenzyme beginning since the 1st postoperative day.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine.

SUBSTANCE: method involves detecting pathological changes and setting diagnosis. Biologically active points corresponding to the disease and points or zones of Zakharyin-Gedda with low electric resistance are determined. Constant action is first applied to them with DC intensity of 1-10 mcA. Electric stimulation intensity is increased to reach sensory response of a patient. Then, magnetic infrared laser therapy is applied.

EFFECT: enhanced effectiveness of treatment; accelerated treatment course.

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-2% aqueous solution of photosensibilizer agent of chlorine series. After accomplishing enucleation, scanning laser radiation of muscle funnel cavity is carried out. Muscle funnel cavity tamponade is done with two implant components. The implant is manufactured from carbon felt impregnated with photosensibilizing gel based on hyaluronic acid viscoelastic. The gel has 0.1-1 % by mass of photosensibilizer of chlorine series. The first implant component is placed at the beginning. Scanning laser radiation of muscle funnel cavity with the first implant component being arranged therein, is carried out during 2-4 min after 15-30 min long exposure away from light action. The second implant component is placed. Scanning laser radiation of muscle funnel cavity after 15-30 min long exposure away from light action is carried out in the same mode. Muscles are sutured. Soft tissues are sutured layer-by-layer. The postoperative space is drained. Sutures are placed on conjunctiva. Eye prosthesis is set and eyelids are sutured to each other. Photosensibilizer agent of chlorine series is repeatedly introduced into cubital vein of one of the arms. 5-15 min later, intravenous laser radiation treatment of blood is carried out via laser light guide introduced into cubital vein of one of the other arm, during 10-45 min with total power of 20-50 mW.

EFFECT: enhanced effectiveness of treatment; excluded soft tissue deformity in orbital region; reduced implant rejection and carcinoma cells metastasis and dissemination risk.

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-1% aqueous solution of photosensibilizer agent of porphyrin or hematoporphyrin series belonging to Photohem or Photophryne group at a dose of 2.5-5.0 mg/kg. After accomplishing enucleation, scanning laser radiation of muscle funnel cavity is carried out. Muscle funnel cavity tamponade is done with two implant components. The implant is manufactured from carbon felt impregnated with photosensibilizing gel based on hyaluronic acid viscoelastic from chealon, viscoate or hyatulon group. The gel has 0.1-1 % by mass of photosensibilizer of porphyrin or hematoporphyrin series belonging to Photohem or Photophryne group. The first implant component is placed at the beginning. Scanning laser radiation of muscle funnel cavity with the first implant component being arranged in it, is carried out during 2-4 min after 15-30 min long exposure away from light action. The second implant component is placed. Scanning laser radiation of muscle funnel cavity after 15-30 min long exposure away from light action is carried out in the same mode. Direct muscles are sutured. Soft tissues are sutured layer-by-layer. The postoperative space is drained. Laser light guide is introduced into cubital vein immediately after enucleation. Intravenous laser radiation treatment of blood is carried out during 10-45 min with total power of 20-50 mW.

EFFECT: enhanced effectiveness of treatment; excluded soft tissue deformity in orbital region; reduced implant rejection and carcinoma cells dissemination risk.

FIELD: medicine.

SUBSTANCE: method involves carrying out vitrectomy, retinotomy, exposing the intraocular neoplasm, surgically removing the intraocular neoplasm, smoothing retina with perfluororganic compound and substituting the perfluororganic compound with silicon oil. After having removed the perfluororganic compound, 10% ozonized Perfluoran emulsion having ozone concentration of 2-4 mg/l is intravenously introduced. Photosensibilizer agent is introduced into cubital vein of the same arm during 5-10 min. Intravenous laser radiation treatment of blood in 5-15 min after beginning photosensibilizer agent injection with wavelength corresponding to maximum light absorption value characteristic of the photosensibilizer agent within 10-45 min under radiation power required for activating photochemical process. Smoothing retina with perfluororganic compound being completed, separating endoscopic laser coagulation of retinotomy region is carried out with diode laser. 1-3 months later, ozonized Perfluoran emulsion, photosensibilizer agent and intravenous laser radiation treatment are repeatedly applied.

EFFECT: enhanced effectiveness of treatment; reduced risk of tumor cell dissemination.

FIELD: medicine.

SUBSTANCE: method involves carrying out vitrectomy with posterior hyaloid membrane and interior boundary membrane in the central retina zone being withdrawn. Vitreal cavity tamponade with perfluororganic compound and retinal endoscopic laser coagulation are carried out. The perfluororganic compound is removed or substituted with physiologic saline or silicon oil in the course of operation. Tunnel is formed in sub-Tenon space after having sealed the eyeball and restored intraocular pressure. Flexible polymer implant covered with hydrogel material is introduced into the tunnel with flat insert manufactured from magnetic material producing permanent magnetic field of 3.5-5 mTesla units with multipolar reversed magnetization. Distal end of the implant having magnetic insert is extrasclerally arranged in the central retina zone edema projection area. The proximal end is sutured to sclera in equatorial zone. 3-5 weeks later, the implant is withdrawn.

EFFECT: enhanced effectiveness of treatment; accelerated retinal edema resorption.

5 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves carrying out vitrectomy with posterior hyaline membrane being removed. Retinotomy is carried out with subretinal neovascular complex being removed. Autogenous pigment retinal epithelium is subretinally introduced through retinotomy area as stratum or suspension. The intravitreous tamponade is carried out with perfluororganic compound substituted with air next to it. Flexible polymer magnetolaser implant having ring-shaped magnet with axial permanent magnetic field magnetization of 3-7 mTesla units is extrasclerally mounted into tunnel built between sclera and Tenon's capsule in macular area projection zone. The implant is turned with S pole towards transplanted cells so that laser radiation-emitting lens is arranged in their projection zone. Implant light guide is sutured to sclera 5-6 mm far from limb. The implant is covered with conjunctiva. Light guide outlet is attached to temple. The introduced cells are treated via laser light guide and implant lens with divergent continuous laser radiation. The magnetic implant is removed after having finished the treatment course and sutures are placed on conjunctiva.

EFFECT: enhanced effectiveness of treatment.

FIELD: medicine.

SUBSTANCE: method involves taking fibrinous exudates from the anterior chamber, pupil area, iris and from vitreous body cavity to carry out bacteriological analysis. Closed subtotal vitrectotmy is carried out with maximum exudates and inflammatory membranes being removed from the vitreous cavity. A photosensibilizer agent is introduced into the vitreous cavity and hold without being exposed to light action during 10-1t5 min. Photodynamic therapy with endolaser radiation treating the vitreous cavity is applied by applying intravitreous light guide with wavelength of 661-666 nm. The vitreous cavity tamponade with silicon oil is carried out and antibacterial preparations are introduced. The photosensibilizer agent is introduced into the anterior chamber and the anterior chamber is irradiated with coaxial halogen lamp light via corneal paracentesis with red light filter being used.

EFFECT: enhanced effectiveness of treatment; eliminated endophthalmitis symptom manifestations; retained anatomical correspondence of ophthalmic tunics; excluded early stage eye evisceration.

3 cl

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine, applicable for stopping of pains of various nature.

SUBSTANCE: the device has a quantum-mechanical oscillator located in a casing, magnet, vessel for medicinal agent and a hollow cylinder. The magnet is installed between the oscillator and the vessel. Positioned in the vessel is a hollow cylinder having through holes on its surface.

EFFECT: quick and absolute anestesia.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves administering laser radiation therapy once a day using low intensity pulsating radiation of wavelength equal to 890nmand power density of 0.03 mW/cm2. Injured organ projection to frontal abdominal wall is exposed to radiation at the first laser therapy stage in two fields acting upon each field for 2 min with radiation pulse succession frequency equal to 80 Hz in applying stable contact-type method. Total treatment dose on two fields is equal to 0.008 J/cm2. The second laser therapy stage begins immediately after having finished the first one in applying radiation along the large intestine path using labile contact-type method in a way that radiation pulse succession frequency equal to 80 Hz is applied first during 1 min and then frequencies of 600, 150 and 300 Hz are applied also during 1 min, respectively. Total treatment dose is equal to 0.032 J/cm2 at the second stage. Total treatment dose is equal to 0.04 J/cm2 at both stages.

EFFECT: enhanced effectiveness in inhibiting dysbacteriosis; reduced frequency of postoperative complications.

Up!